NCT04818255Completed
STIM+: PET Biomarker Education & Disclosure
Stimulation to Improve Memory: PET Education & Disclosure
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging. Studies have shown that changes in the brain happen before full symptoms of DAT develop. These changes include a buildup of two proteins within the brain, called amyloid and tau. The two goals of this study are (1) to determine whether patients with mild cognitive impairment or dementia-Alzheimer's type (DAT) are able to demonstrate decisional capacity to engage in PET amyloid and tau disclosure after receiving education; and (2) to assess how patients and care partners react to PET amyloid and tau biomarker disclosure.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 152 (actual)
- First submitted
- 3 Mar 2021
- Start date
- 10 Dec 2020
- Primary completion date
- 7 Nov 2024
- Lead sponsor
- University of Michigan
- Diseases
- Alzheimer disease
- NCT number
- NCT04818255
What you commit to
- Study type: Interventional
- Participants enrolled: 152
- From 10 Dec 2020 to the primary completion date, 7 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Newly diagnosed neurologic disease (since completion of Stimulation to Improve Memory Study activities)
Other
- Active diagnosis of moderate depression or anxiety without treatment
Who the study is looking for
- Enrolled in the Stimulation to Improve Memory Study (NCT03875326).
- Completed PET scan with amyloid and/or tau tracer success.
- Demonstrates decision-making capacity to engage in PET disclosure, or has a care partner in attendance that demonstrates decision-making capacity for the participant to engage in disclosure
- If diagnosed with DAT: must have a cognitively intact study partner (i.e., their care partner)
- If diagnosed with MCI: strongly recommended to have a cognitively intact study partner (i.e., their care partner)
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Medical School, Department of Psychiatry Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.